Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 98

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 98
---
; |

| ● | substantial monetary awards to trial participants or patients; |

| ● | product recalls, withdrawals or labeling, marketing or promotional restrictions; |

| ● | loss of revenue; and |

| ● | exhaustion of any available insurance and our capital resources. |

We will incur increased costs and become subject to additional regulations and requirements as a result of becoming a public company, which could lower our profits or make it more difficult to run our business.

As a public company, we will
incur significant legal, accounting and other expenses that we have not incurred as a private company, including costs associated with
public company reporting requirements. We also have incurred and will continue to incur costs associated with the Sarbanes-Oxley Act,
and related rules implemented by the Securities and Exchange Commission, or SEC, and the exchange our securities are listed on. The expenses
generally incurred by public companies for reporting and corporate governance purposes have been increasing. We expect these rules and
regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although
we are currently unable to estimate these costs with any degree of certainty. These laws and regulations also could make it more difficult
or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations
could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on our board committees
or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting
of our common stock, fines, sanctions, other regulatory action and potentially civil litigation.

We are an Emerging Growth Company

We are an “emerging growth
company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). We will remain an emerging
growth company until the earlier of (i) December 31, 2026, the last day of the fiscal year following the fifth anniversary
of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii) the
last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (iii) the date on which
we have issued more than $1 billion in nonconvertible debt during the previous